Reduction in the number of active myofibroblasts and in liver and serum TGF-β1 levels in SPARC deficient fibrotic mice.
- Catalina Atorrasagasti (281161)
- Estanislao Peixoto (281162)
- Jorge B. Aquino (281163)
- Néstor Kippes (281164)
- Mariana Malvicini (281165)
- Laura Alaniz (281166)
- Mariana Garcia (281167)
- Flavia Piccioni (281168)
- Esteban J. Fiore (281169)
- Juan Bayo (281170)
- Ramón Bataller (136853)
- Elizabeth Guruceaga (46989)
- Fernando Corrales (172839)
- Osvaldo Podhajcer (281171)
- Guillermo Mazzolini (281172)
DOIAbstract
<p>(A–H) Representative pictures taken from liver sections of untreated SPARC<sup>+/+</sup> and SPARC<sup>−/−</sup> (A,B), 10 weeks TAA treated SPARC<sup>+/+</sup> (C,E) andSPARC<sup>−/−</sup> (D,F), or BDL SPARC<sup>+/+</sup> (G) and SPARC<sup>−/−</sup> (H) mice immunostained for α-SMA. (E,F) are higher magnification images from box areas in C,D respectively. (I) Quantitative data of densitometric analyses of αSMA immunostained area from TAA-treated and BDL SPARC<sup>−/−</sup> or SPARC<sup>+/+</sup> mice. **p<0.01, Mann-Whitney test. (J) Quantitative data of TGF-β1 mRNA levels obtained by qPCR analysis from 10 weeks TAA-treated and BDL SPARC<sup>+/+</sup> or SPARC<sup>−/−</sup> mice (n = 6–8). Data are expressed as relative values to thos...